Format

Send to

Choose Destination
See comment in PubMed Commons below
Arch Neurol. 2012 Aug;69(8):1002-10.

Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.

Collaborators (172)

Doody R, Rosentree S, Awosika-Olumo S, Sims J, Chowdhury M, Brody M, Watson D, Bouchard C, Barbati G, Brody L, Sperling R, Marshall G, Wolk D, Vliet M, Salisbury S, Rentz D, Salloway S, Malloy P, Blackham B, Correia S, Cimini D, Sabbagh M, Ceimo J, Lopez J, Davis K, Connor D, Solomon P, Catapane-Friedman L, Levin P, Holland C, Robinson M, Bell K, Honig L, Dominguez-Rivera E, Tejeda R, Canaan A, Beyer J, Doraiswamy R, Gersing K, Aiello M, Husn H, Aisen P, Ward C, Behan K, Reynolds B, Hake A, Evans R, Van Hook E, Cavanaugh K, Rexroth D, Graff-Radford N, Boughey J, Fletcher R, Parfitt F, Makarov L, Knopman D, Boeve B, Haukom N, Johnson K, Bailey K, Wytaske K, Quinn J, Kaye J, Gilmore T, Wild K, Ferguson F, Wilcox C, Morrissey J, Hardy A, Myrant W, Grosz D, Schneider A, Morrissey J, Myrant W, Wilcox C, Taber L, Kirby L, McCarthy C, Footer T, Fadden S, Christensen J, Borwege S, Aggarwal N, Shah R, Lopez-Barbera N, Carroll S, Vidaurri M, Ross J, Shi Y, Ponugoti P, Garcia W, McGlue L, Doyle K, DeCarli C, Seavery W, Conover C, Sweeny K, Levallois M, Campos J, Faulstich B, Boxer A, Miller B, Koestler M, Arnold K, Belfor N, Gearhart R, Barbas N, Heidebrink J, Lord J, Guidotti L, Freymuth A, Corey-Bloom J, Tong G, Wetzel K, Wilson A, Tong G, Mulnard R, Thai G, McAdams-Ortiz C, Yanez B, Lopez O, Dekosky S, Klunk W, Macedonia L, Sarles B, Baumgartner T, Porsteinsson A, Tariot P, Goldstein B, LaFountain J, Terwilliger L, Rosenberg R, Womack K, Svetlik D, Moser K, Davis B, Raskind M, Peskind E, Eliza S, Brown N, Petrie E, Morris J, Galvin J, Tomlinson C, Overkamp W, Schneider S, van Dyck C, Tampi R, Estok K, MacAvoy M, Barcelos N, Benincasa A, Sazon M, Lehtinen T, Kailajarvi M, Hilli J, Ruokomäki P, Virtanen K, Kaila T, Koutu M, Toikka T, Scheinin M, Rossor M, Knight W, Douglas J, Warren J, Ridha B, Bullock R, Narayan A, Ventkatesh K, Hall C, Cartwright H.

Author information

1
Clinical Neurochemistry Laboratory, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden. kaj.blennow@neuro.gu.se

Abstract

BACKGROUND:

Given the slow and variable clinical course of Alzheimer disease, very large and extended clinical trials are needed to identify a beneficial clinical effect of disease-modifying treatments. Therefore, biomarkers are essential to prove that an anti-β-amyloid (Aβ) drug candidate affects both Aβ metabolism and plaque load as well as downstream pathogenic mechanisms.

OBJECTIVE:

To evaluate the effect of the anti-Aβ monoclonal antibody bapineuzumab on cerebrospinal fluid (CSF) biomarkers reflecting Aβ homeostasis, neuronal degeneration, and tau-related pathology in patients with Alzheimer disease.

DESIGN:

Two phase 2, multicenter, randomized, double-blind, placebo-controlled clinical trials of 12-month duration.

SETTING:

Academic centers in the United States (Study 201) and England and Finland (Study 202).

PATIENTS:

Forty-six patients with mild to moderate Alzheimer disease.

INTERVENTIONS:

Patients received either placebo (n = 19) or bapineuzumab (n = 27) in 3 or 4 ascending dose groups.

MAIN OUTCOME MEASURES:

Changes between end of study and baseline in the exploratory CSF biomarkers Aβ1-42, AβX-42, AβX-40; total tau (T-tau); and phosphorylated tau (P-tau).

RESULTS:

Within the bapineuzumab group, a decrease at end of study compared with baseline was found both for CSF T-tau (-72.3 pg/mL) and P-tau (-9.9 pg/mL). When comparing the treatment and placebo groups, this difference was statistically significant for P-tau (P = .03), while a similar trend for a decrease was found for T-tau (P = .09). No clear-cut differences were observed for CSF Aβ.

CONCLUSIONS:

To our knowledge, this study is the first to show that passive Aβ immunotherapy with bapineuzumab results in decreases in CSF T-tau and P-tau, which may indicate downstream effects on the degenerative process. Cerebrospinal fluid biomarkers may be useful to monitor the effects of novel disease-modifying anti-Aβ drugs in clinical trials. TRIAL REGISTRATIONS clinicaltrials.gov Identifier: NCT00112073, EudraCT Identifier: 2004-004120-12, and isrctn.org Identifier: ISRCTN17517446.

PMID:
22473769
DOI:
10.1001/archneurol.2012.90
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center